ornidazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antiprotozoals and radiosensitizers, metronidazole derivatives 1997 16773-42-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ornidazole
  • ornidal
  • ornidone
  • ornilox
  • ornisid
  • ornitop
A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.
  • Molecular weight: 219.63
  • Formula: C7H10ClN3O3
  • CLOGP: 0.06
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 81.19
  • ALOGS: -1.82
  • ROTB: 4

Drug dosage:

DoseUnitRoute
1 g P
1.50 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 1.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.08 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.88 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 98 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.723 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.268 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 49.204 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 3.266 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 78.910 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 83.240 % Moderate 0.72
herg hERG pIC50 4.009 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 1.563 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 3.548 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 80.800 % Moderate 0.72
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKDC,STK33,SYK,TEK,TTK,ZAP70 39
kinase-selectivity-class AXL,CDK9,DYRK1B,GRK2,MAP2K6,MAPK7,TEK,TTK 8
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.495 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 12.303 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 80.540 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 6.194 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 80.650 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 7.063 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 95.630 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 75.040 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 912.011 uM Moderate 0.72

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G01AF06 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
ATC J01RA05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA15 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01XD03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Imidazole derivatives
ATC P01AB03 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
Nitroimidazole derivatives
MeSH PA D000563 Amebicides
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D000994 Antitrichomonal Agents
MeSH PA D011838 Radiation-Sensitizing Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35820 antiprotozoal drug
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:50685 antitrichomonal drug
CHEBI has role CHEBI:53000 epitope
CHEBI has role CHEBI:171664 antiamoebic agent

Related Drugs by ATC class:

G01AF Imidazole derivatives 16 drugs
azanidazolebutoconazoleclotrimazoleeconazolefenticonazoleflutrimazoleisoconazoleketoconazolemetronidazolemiconazoleomoconazoleoxiconazole show all 16 →
J01RA Combinations of antibacterials 18 drugs
amikacinazithromycincefepimecefiximecefuroximeciprofloxacinfluconazolelevofloxacinmetronidazolenitazoxanidenorfloxacinnystatin show all 18 →
J01XD Imidazole derivatives 2 drugs
metronidazoletinidazole
P01AB Nitroimidazole derivatives 7 drugs
azanidazolefurazolidonemetronidazolenimorazolepropenidazolesecnidazoletinidazole

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.97 acidic
pKa2 2.4 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000167081 NUI
D05274 KEGG_DRUG
C0029274 UMLSCUI
CHEBI:75176 CHEBI
CHEMBL1449676 ChEMBL_ID
DB13026 DRUGBANK_ID
D009950 MESH_DESCRIPTOR_UI
28061 PUBCHEM_CID
3319 INN_ID
62XCK0G93T UNII
7701 RXNORM
005696 NDDF
442845007 SNOMEDCT_US
442924004 SNOMEDCT_US

Pharmaceutical products:

None